Auxilium Pharmaceuticals Announces Top-Line Results From A Pivotal Efficacy Study Of AA4500 In Dupuytren's Disease

AuxiliumPharmaceuticals, Inc. (Nasdaq: AUXL) today reported top-line results from apivotal efficacy study of AA4500, its injectable enzyme product, inpatients with Dupuytren's Disease. The Company also announced its decisionto pursue additional sources of commercial supply for AA4500 and revisedfinancial guidance with respect to Research and Development costs andfull-year loss for 2006. [click link for full article] (Source: Infectious Diseases / Bacteria / Viruses News From Medical News Today)

MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

Read More... [Source: MedWorm: Dupuytren's Contracture - Posted by FreeAutoBlogger]